Healthcare, Pharma & Life Sciences

WuXi XDC Licenses ADC Payload Platform to Ona Therapeutics

Image
WuXi XDC Licenses ADC Payload Platform to Ona Therapeutics

Shanghai – September 20, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.

Deal structure includes upfront payment, milestones and tiered royalties

The agreement grants Ona Therapeutics exclusive global rights to develop an ADC candidate using WuXi XDC's WuXiTecan-2 platform. The total potential deal value comprises an upfront payment plus development, regulatory and sales milestone payments, with WuXi XDC also eligible for tiered royalties on net sales once the resulting product reaches commercialization. WuXi XDC will additionally provide chemistry, manufacturing and controls (CMC) development and manufacturing support through its integrated ADC CRDMO platform.

CU Anschutz Study: Post-Concussion Irritability Tied to PTSD, Pain, Hearing

Image
CU Anschutz Study: Post-Concussion Irritability Tied to PTSD, Pain, Hearing

Aurora, Colo. – September 20, 2026 -- A new study from the University of Colorado Anschutz Marcus Institute for Brain Health finds that irritability following chronic mild traumatic brain injury (mTBI) in military veterans stems from a combination of PTSD symptoms, chronic pain and difficulty understanding speech in noisy environments, not a single psychological cause.

Study of 124 veterans links irritability to three distinct factors

Published in the Journal of Neuropsychiatry and Clinical Neurosciences, the research examined 124 military veterans, including 61 with chronic mTBI and 63 without any history of brain injury. Participants underwent standardized assessments measuring irritability, PTSD symptoms, chronic pain, balance and auditory processing, including speech-in-noise comprehension.

111 Inc Reports Widened Q2 Loss as Promotional Product Revenue Jumps 121%

Shanghai – September 20, 2026 -- 111, Inc. (NASDAQ: YI) reported a net loss of RMB31.7 million (US$4.7 million) for the second quarter of 2026, more than four times the RMB7.3 million loss posted a year earlier, as the Shanghai-based healthcare platform accelerated its shift away from an asset-heavy distribution model.

Net revenue falls 28.3% as company sheds underperforming subsidiaries

Net revenue totaled RMB2.3 billion (US$339.0 million), down from RMB3.2 billion in the prior-year quarter. The company attributed the decline to last year's divestiture of several underperforming subsidiaries, part of a strategy to generate more service-based commission income and reduce operational and capital risk.

Clarivate Names 22 Citation Laureates, Honoring GLP-1 Drug Pioneers

Image
Clarivate Names 22 Citation Laureates, Honoring GLP-1 Drug Pioneers

London – September 20, 2026 -- Clarivate Plc (NYSE: CLVT) named 22 researchers as its Citation Laureates 2026, identifying scientists whose work the company's Institute for Scientific Information (ISI) considers Nobel-class ahead of this year's Nobel Prize announcements. Since the program began in 2002, 89 previously named Citation Laureates have gone on to win Nobel Prizes.

MindMaze Therapeutics to Launch Tablet-Based MindMotion Lite by Year-End 2026

Geneva – September 20, 2026 -- MindMaze Therapeutics (SIX: MMTX) will launch MindMotion Lite by the end of 2026, a tablet-based neurorehabilitation device designed to cut home deployment costs and expand access to intensive stroke and neurological therapy outside clinical settings.

Tablet format replaces bulky hardware for home use

MindMotion Lite delivers the full range of neurotherapeutic activities currently available on the company's MindMotion GO system through a tablet interface, reducing the hardware footprint required for in-home deployment. The device retains full-body rehabilitation training capacity while streamlining the user experience for patients managing therapy at home. It also supports teleconsultation and remote management, allowing clinicians to monitor and adjust treatment plans as patients continue therapy beyond the clinic.

Sobi-Innate Pharma Deal Turns Effective, Triggers $75M Payment

Stockholm – September 20, 2026 -- Swedish Orphan Biovitrum AB (Sobi) has paid Innate Pharma SA USD 75 million as their strategic oncology partnership becomes legally effective, following the expiration of antitrust waiting periods and satisfaction of other closing conditions.

Partnership clears regulatory hurdles first announced September 20, 2026

The deal, initially disclosed on September 20, 2026, grants Sobi exclusive global commercialisation rights to lacutamab pending accelerated approval, with an option to assume full global development rights if Phase 3 results are positive.

Robinson Pharma Wins Bausch + Lomb Award After $115M Expansion

Image
Robinson Pharma Wins Bausch + Lomb Award After $115M Expansion

Santa Ana, Calif. – September 20, 2026 -- Robinson Pharma, Inc. (RPI) has received the "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026, recognizing sustained operational performance following a $115 million infrastructure expansion.

Robinson Pharma completes $115 million facility expansion across Southern California

The contract manufacturer finalized a $75 million purchase of a 261,000-square-foot facility in Irvine near John Wayne Airport, adding to a prior $40.7 million acquisition in Santa Ana. The combined investments push Robinson Pharma's regional manufacturing footprint beyond one million square feet.

Company secures USP certification after clearing quality audits

Robinson Pharma achieved United States Pharmacopeia (USP) certification following the expansion, adding to its existing FDA, NSF GRMA, UL GMP, SQF, CCOF, and SCCI credentials.

Armor Health Expands Postpartum Depression Care in Correctional Facilities

Image
Armor Health Expands Postpartum Depression Care in Correctional Facilities

Miami – – September 20, 2026 -- Armor Health is scaling a structured postpartum depression (PPD) care framework across correctional facilities nationwide, targeting a patient population it identifies as facing heightened mental-health risk during incarceration.

Armor builds a four-pillar clinical pathway for postpartum inmates

The framework rests on early screening, prevention, structured treatment, and evidence-based clinical guidelines, designed to catch PPD early and maintain continuity of care as patients transition from custody back to their communities.

Adora Life Science Names Dr. Clinton Morgan Chief Medical Officer

Franklin, Tennessee – September 20, 2026 -- Adora Life Science has appointed Dr. Clinton D. Morgan, MD, as its full-time Chief Medical Officer, effective September 20, 2026, the company announced.

Neurosurgeon exits clinical practice to lead human trials for veterinary-derived drug

Dr. Morgan previously served on Adora's Board of Directors and consulted part-time on the company's human therapeutic strategy. In his new role, he will direct Adora's human clinical development, regulatory strategy, and scientific research network, and will chair a newly assembled Scientific Advisory Board spanning glycobiology, osteoarthritis, and radiation injury experts.

Diagnostic Imaging Market to Hit $33.2B by 2031 as AI Reshapes Scanners

Image
Diagnostic Imaging Market to Hit $33.2B by 2031 as AI Reshapes Scanners

Sheridan, Wyo. – September 19, 2026 -- The global diagnostic imaging market will expand from $26.5 billion in 2026 to $33.2 billion by 2031, a 4.6% compound annual growth rate, according to a new study by Wissen Research.

AI moves inside the scanner, cutting exam times sharply

Deep learning reconstruction algorithms are now embedded directly into image acquisition pipelines rather than applied after scanning. GE HealthCare's Sonic DL sequence allows complex multi-sequence brain and joint MRI protocols to complete in under 15 minutes, letting hospitals raise per-scanner throughput without new capital equipment. Radiology remains the top specialty for AI device clearances, with more than 1,100 cleared by the U.S. FDA to date.